Preparation of human ovarian cancer ascites-derived exosomes for a clinical trial.
暂无分享,去创建一个
L. Zitvogel | M. Mason | A. Clayton | B. Jasani | J. Hobot | H. Navabi | L Zitvogel | A Clayton | H Navabi | M Adams | M D Mason | B Jasani | Z. Tabi | Z Tabi | D Croston | J Hobot | R Bailey-Wood | K Wilson | Malcolm Adams | M. Adams | D. Croston | R. Bailey‐Wood | K. Wilson | K. WIlson | R. Bailey-Wood
[1] George Coukos,et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival , 2004, Nature Medicine.
[2] Laurence Zitvogel,et al. Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming , 2001, Nature Medicine.
[3] L. Turka,et al. Toll-Like Receptor Ligands Directly Promote Activated CD4+ T Cell Survival , 2004, The Journal of Immunology.
[4] M. Mason,et al. Recovery of CD8+ T-cell function during systemic chemotherapy in advanced ovarian cancer. , 2005, Cancer research.
[5] T. Eberlein,et al. Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[6] M. Loveless,et al. A controlled clinical trial with a specifically configured RNA drug, poly(I).poly(C12U), in chronic fatigue syndrome. , 1994, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[7] J. Le Pecq,et al. Production and characterization of clinical grade exosomes derived from dendritic cells. , 2002, Journal of immunological methods.
[8] V. Devita,et al. A phase I-II trial of multiple-dose polyriboinosic-polyribocytidylic acid in patieonts with leukemia or solid tumors. , 1976, Journal of the National Cancer Institute.
[9] L. Zitvogel,et al. Exosomes as Potent Cell-Free Peptide-Based Vaccine. II. Exosomes in CpG Adjuvants Efficiently Prime Naive Tc1 Lymphocytes Leading to Tumor Rejection 1 , 2004, The Journal of Immunology.
[10] B. Robinson,et al. Immunotherapy and chemotherapy — a practical partnership , 2005, Nature Reviews Cancer.
[11] George Coukos,et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. , 2003, The New England journal of medicine.
[12] G. Coukos,et al. TRANCE- and CD40 ligand-matured dendritic cells reveal MHC class I-restricted T cells specific for autologous tumor in late-stage ovarian cancer patients. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[13] L. Zitvogel,et al. Malignant effusions and immunogenic tumour-derived exosomes , 2002, The Lancet.
[14] Simon C Watkins,et al. Endocytosis, intracellular sorting, and processing of exosomes by dendritic cells. , 2004, Blood.
[15] R. Flavell,et al. Recognition of double-stranded RNA and activation of NF-κB by Toll-like receptor 3 , 2001, Nature.
[16] M. Markman,et al. Primary ovarian cancer chemotherapy: current standards of care , 2003, British Journal of Cancer.
[17] P. V. van Diest,et al. T cell infiltration and MHC I and II expression in the presence of tumor antigens: An immunohistochemical study in patients with serous epithelial ovarian cancer. , 2001, European journal of obstetrics, gynecology, and reproductive biology.
[18] D. Atanackovic,et al. Characterization of Effusion-Infiltrating T Cells , 2004, Clinical Cancer Research.